A detailed history of Ameritas Investment Partners, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 6,570 shares of VERV stock, worth $37,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,570
Previous 6,570 -0.0%
Holding current value
$37,908
Previous $32,000 3.13%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$10.81 - $17.96 $16,539 - $27,478
1,530 Added 30.36%
6,570 $87,000
Q3 2023

Nov 13, 2023

BUY
$11.42 - $20.82 $9,718 - $17,717
851 Added 20.32%
5,040 $66,000
Q2 2023

Aug 11, 2023

BUY
$13.34 - $19.9 $8,297 - $12,377
622 Added 17.44%
4,189 $78,000
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $11,566 - $30,702
740 Added 26.18%
3,567 $122,000
Q1 2022

May 13, 2022

BUY
$20.92 - $39.36 $33,806 - $63,605
1,616 Added 133.44%
2,827 $65,000
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $55,706 - $89,601
1,211 New
1,211 $57,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $346M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.